• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login

  About Us

  About the Journal

Cancer Translational Medicine is a peer-reviewed online journal with Bimonthly print on demand compilation of issues published. The journal is sponsored by Chinese Anti-Cancer Association (CACA) and American Chinese Medical Association (ACMA). It is owned by Xi'an Moshan Biotechnology and Information Co., Ltd. (http://www.moshanbio.com/). The journalís full text is available online at http://www.cancertm.com. It allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

  About CACA and ACMA

The journal is sponsored by Chinese Anti-Cancer Association (CACA) and American Chinese Medical Association (ACMA). CACA was established in 1984. The vision of CACA is to be the leading non-governmental organization devoted to increase the survival rate, decrease the incidence and mortality rate of cancer, and improve the cancer control in China and the world. The mission of CACA is to contribute to the prevention and treatment of cancer via organizing, mobilizing and supporting clinical, scientific and technological professionals in the field of oncology.

ACMA was established in 1998. ACMA aims to be a premier American-Chinese academic medical organization. The mission of ACMA is to combine the power of Eastern and Western Medicine to improve health for all, promote healthcare delivery, medical education and training, and community service, bridge the gap between medical research and clinical practice, and function as a bridge for healthcare professionals between US and China.

  Scope of the journal

The journal covers innovative basic, clinical and translational cancer research studies that bridge the laboratory and the clinic. Cancer Translational Medicine is especially interested in cancer risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and experimental therapeutics in the field of chemotherapy, radiotherapy and biotherapy (immune-therapy, gene-therapy, target-therapy, stem-cell-therapy and so on). Examples of content include:

  • Translational, clinical, preventative, and epidemiologic cancer research
  • Molecular and cellular level researches that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression
  • New molecular mechanisms and interactions that support cancer phenotypes
  • An incisive rationale that could interest a broad audience
  • A generalizable conclusion with potentially broad impact

Potential Audience: Researchers focus on basic and translational cancer study, physician scientists, students, funding agencies, business developers

    Medknow Publications   Top
Editorial board
Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal